Liver Metastases Colorectal Cancer

Therefore the treatment of liver metastases is a very important determinant of outcome in many patients with metastatic colorectal cancer.

Liver metastases colorectal cancer.

Metastatic colorectal cancer is cancer that began in the colorectal area but has spread to other parts of your body. Treatment will depend on where the cancer has spread and the stage of that cancer. Although some types of metastatic cancer can be cured with current treatments most cannot. Jaundice or swelling in the belly when cancer has spread to the liver.

Studies show hepatic resection is the only modern treatment offering long term survival. Cancer that starts in your colon can sometimes spread to other parts of your body including the liver. Treatment for metastatic cancer. And for a small group of people with cancer that has only spread to your liver or lung surgery might even cure it.

Once cancer spreads it can be hard to control. Another name for it is metastatic or stage iv colon cancer. Colorectal liver cancer metastatic patients have the best chances of survival with surgical resection giving them an almost 58 percent five year survival rate. While colorectal cancer liver metastases may be accompanied by other sites of metastatic disease the liver is commonly the only or the dominant metastatic site.

They are the cells from the part of the body where the primary cancer began for example cancerous breast colon or lung. Over the last 20 years and the last decade in particular the clinical outcome for patients with metastatic colorectal cancer has improved greatly due not only to an increase in the number of patients being referred for and undergoing surgical resection of their localised metastatic disease but also to a more strategic approach to the delivery. Even so there are treatments for all patients with metastatic cancer. The treatment of resectable colorectal cancer metastases to the liver has undergone changes with the addition of active chemotherapeutic agents innovations and definition in the surgical procedures understanding of the benefits and toxicities of the surgical and chemotherapeutic cytotoxic and biologic interventions and use of the team approach.

However research continues to increase the number of patients who qualify for resection.